Verdad Advisers’s Tenax Therapeutics TENX Stock Holding History

Verdad Advisers’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.79M	Buy	123,174 +27,844	+29%	+$356K	1.72%	6
2026 Q1	$1.52M	Buy	+95,330	New	+$1.29M	1.72%	9

Other funds holding TENX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Verdad Advisers's TENX Position: Q2 2026 in Review

Verdad Advisers increased its Tenax Therapeutics (TENX) stake by 29% in Q2 2026, buying an estimated $356K and bringing the position to 123,174 shares worth $1.79M. The position accounts for 1.72% of the portfolio, ranked #6.

Verdad Advisers first reported a position in TENX in Q1 2026 and has held it in 2 quarters since. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

Verdad Advisers held 123,174 shares of Tenax Therapeutics worth $1.79M as of Q2 2026.
Verdad Advisers bought 27,844 Tenax Therapeutics shares in Q2 2026, an estimated $356K.
Tenax Therapeutics made up 1.72% of Verdad Advisers's portfolio in Q2 2026, its #6 holding.
Verdad Advisers first reported a position in Tenax Therapeutics in Q1 2026 and has held it in 2 quarters since.
111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.